Media
April 10-15 and May 17-21, 2021, 4HF will participate in the virtual AACR ANNUAL MEETING
Our E-Posters:
"ProLiFiler and Cancer Data Miner, combined platforms for preclinical investigation to scrutinize impact of inhibitors on the KRAS, PI3K and MDM2 signaling pathways" by V. Vuaroqueaux et al.;
Session Category: Experimental and Molecular Therapeutics; Session Title: Cellular Responses to Anticancer Drugs; Permanent Abstract No.#1027
"MACC1 overexpression in colorectal cancer is driven by chromosomal instability and is associated with molecular subtype" by V. Vuaroqueaux et al.; Session Category: Tumor Biology;
Session Title: Invasion and Metastasis 2; Permanent Abstract No. #2879
"Identification of novel targets for the treatment of pancreatic cancer patients" by A.-L. Peille et al.; Session Category: Experimental and Molecular Therapeutics; Session Title: Identification of Molecular Targets; Permanent Abstract No. #1173
"Identification of a promising renal cell carcinoma target using a unique in silico approach"
by A. Musch et al.; Session Category: Experimental and Molecular Therapeutics;
Session Title: Identification of Molecular Targets; Permanent Abstract No. #LB107
------------------------------------
March 8-11, 2020, 4HF Biotec participates in the 11th World ADC Europe conference on antibody-drug conjugates
------------------------------------
January 29, 2021, an interview was published on the online news platform GenomeWeb between Vincent Vuaroqueaux of 4HF Biotec and GenomeWeb editor Neil Versel: "4HF Biotec Banking on Multiomic Data Analysis to Help Pharma find new Oncology Compounds"
------------------------------------
October 24 - 25, 2020, 4HF Biotec presented at the annual 32th EORTC-NCI-AACR Symposium (virtual) on Molecular Targets and Cancer Therapeutics
Our E-Poster:
“An advanced in silico drug discovery platform, 4HF Biotec's Data miner for identifying novel targets for tumors and tumor-stroma” by S. Das et al. , #105
------------------------------------
October 19, 2020, 4HF Biotec announced that it entered into a collaboration with Reaction Biology, a drug discovery CRO with offices in Germany and USA, on a new cell-based service offering
------------------------------------
November, 2019, an article in MIRROR REVIEW was published "4HF BIOTEC: A Novel Approach For Cancer Treatment"
-----------------------------------
October 26 - 30, 2019, 4HF Biotec presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston
Our Posters :
“The use of 4HF Cancer Data Miner platform for an In Silico pharmacogenomic study predicting tumor response to the CDK4/6 inhibitor Palbociclib”
Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Session Date: Tuesday, October 29 -12.30 -16 PM; #C075
“Broad spectrum activity of the MDM2 inhibitor MI-773 in hematologic and solid cancer cell lines
in-vitro and determination of predictive biomarkers”
Session Title: Therapeutic Agents - Other
Session Date: Tuesday, October 29 -12.30 -16 PM; #C060
-----------------------------------
October 8 -11, 2019, 4HF Biotec presented in collaboration with Bionavigen at 10th Annual World ADC, San Diego
Our Poster:
"4HF Cancer Data Miner platform for an accelerated
In Silico ADC target discovery and evaluation"; No. #01
-----------------------------------
July, 2019, StartupCity selected 4HF Biotec in the top 15 most promising Biotec startups in Europe
Links:
https://biotech-europe.startupcity.com/vendors/top-biotech-startups-in-europe-2019.html
-----------------------------------
July 18, 2019, 4HF Biotec announced that it entered into a collaboration with Bionavigen in the field of target and drug discovery
-----------------------------------
March 29 - April 3, 2019, 4HF participated in the AACR ANNUAL MEETING in Atlanta, USA
Our Posters:
"Strong anti-tumor activity of MEK inhibitor GDC-0623 and determination of predictive biomarkers"; Abstract No. #2196
"Broad spectrum activity of the BET inhibitor GSK 1324726A in hematologic and solid cancer cell lines in-vitro and determination of associated predictive biomarkers"; Abstract No. #3074
------------------------------------
November 13 -16, 2018, 4HF Biotec participated in the 30th EORTC-NCI-AACR SYMPOSIUM: Molecular Targets and Cancer Therapeutics, the premier international meeting featuring novel cancer therapeutics that took place in Dublin, Ireland
Our Poster:
"Broad spectrum activity of Sabutoclax in haematological and solid cancer cell lines is associated with defined biomarkers"; Section "Molecular Targeted Agents" on November 13, 2018; #PB-039
------------------------------------
April 14 - 18, 2018, 4HF Biotec participated in the AACR ANNUAL MEETING, Chicago, USA
-----------------------------------
February 7 - 10, 2018, 4HF Biotec participated in the 39th EORTC-PAMM Winter Meeting in Roma, Italy
-----------------------------------
October 26 - 30, 2017, 4HF Biotec participated in the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, the premier international meeting featuring novel cancer therapeutics, Philadelphia, USA
Our Poster:
”KRAS gene mutations are associated with tumor resistance toward the LN1222/AD736
p38 Inhibitor” on October 29, 2017; #B167